ARS Pharma and Recordati agree deal for epinephrine auto-injector

23 September 2020

ARS Pharmaceuticals has entered into an exclusive licensing agreement with Italian drugmaker Recordati (RECI: MI) for marketing rights in the EU, UK and several other countries for ARS-1, an epinephrine nasal spray.

Known as Neffy in the USA, the product is used to allow at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis.

ARS will continue to seek regulatory approval in the United States and globally.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK